Fig 1. ABVD treated patients.

A total number of 68 patients were treated with ABVD regimen alone. Mean value of subgroup ± standard error of mean (SEM) is shown. p values are considered significant if <0.05 and are marked bold. Significantly more favorable results were seen in the wild-type A/A genotype group of BLMH SNP A1450G with the St. George Respiratory Questionnaire (SGRQ) (A.), with lung scintigraphy results on the right side (B.). Spirometry revealed significantly more favorable forced vital capacity (FVC) and forced expiratory volume in 1 s (FEV1) results. (C.) Linear regression analysis of BLMH SNP A1450G confirmed these results for the different test methods. (D.) “A”–wild-type, ABVD—adriamycin (doxorubicin), bleomycin, vinblastine, dacarbazine, DTPA—diethylenetriamine penta-acetic acid, FEV₁ –forced expiratory volume in 1 second, FMF—forced mid-expiratory flow, FVC—forced vital capacity, “G”–mutant type, SGRQ—St. George’s Respiratory Questionnaire